At 4 hours of life, he developed coarse jerky movements of all four extremities that lasted approximately 5 minutes and recurred periodically throughout the day. Concerned regarding the infant's drowsy state requiring stimulation to awaken him for feedings, he was transferred to the neonatal intensive care unit for diagnostic evaluation and therapy. On physical exam, the patient was pale yet without physical anomalies. He was difficult to arouse. Coarse rhythmic movements of all four extremities could not be extinguished. The remainder of the physical exam was unremarkable. Blood chemistries, cerebral spinal fluid analysis and cultures, and head computed tomography were normal. Homocysteine level was 5 (normal level) on the first day of life. The electroencephalogram showed spikes in the temporal region. Brain magnetic resonance imaging with venogram showed a superior sagittal sinovenous thrombosis (SVT) and bilateral parietal and frontal lobe infarcts. Investigations to identify inherited risk factors for thrombosis were negative for factor V Leiden mutation and prothrombin G20210A mutation. Relevant plasma protein levels were compared to published normal values for term infants 7 and were as follows: antithrombin III activity 66% (term normal, 41% to 93%), protein C activity 38% (term normal, 20% to 64%), protein C antigen 40% (term normal, 20% to 64%), and free protein S antigen 89%. He was positive for homozygous C677T alleles of MTHFR. The patient was treated with phenobarbital for seizure control to a phenobarbital level of 24 at discharge and empirically started on folic acid supplementation. He had normal kidney and liver function tests. Anticoagulation was not initiated.
Familial screening showed that his mother was also homozygous for the C677T alleles of MTHFR. His father and sibling were heterozygous for the alleles. The mother's homocysteine level was 5 two months post-partum. She began vitamin B 12 and folic acid supplementation. Follow-up at 2, 4, and 6 months of life showed a developmentally normal male infant. He was weaned off his phenobarbital at 4 months of life with no subsequent seizure activity. On subsequent computed tomographies, his thrombosis had neither progressed nor resolved.
DISCUSSION
The superior sagittal sinus drains cortical venous blood into the right lateral sinus and ultimately the jugular vein. Drainage is The C677T mutation in 5,10 -methylenetetrahydrofolate reductase ( MTHFR ) predicts substitution of valine for alanine at residue 223 ( A223V ) . This thermolabile form of MTHFR has 50% reduced activity, has been associated with hyperhomocystinemia, and is a described risk factor for thrombosis in adults. 1 -3 In addition, it has been associated with birth defects in the infants of affected mothers and with recurrent fetal losses. 4 -6 We report the occurrence of sinovenous thrombosis in a newborn infant who presented with seizures. Both infant and mother were subsequently identified as having homozygous C677T alleles for MTHFR. 
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passive and there are no venous valves. Disturbance of normal blood flow in the sinuses, most commonly the superior sagittal, can precipitate thrombus formation and in turn lead to infarction in the affected brain distribution. 8 -10 SVT is most commonly associated with bacterial infection and associated vascular invasion. Non-septic SVT may be caused by a number of processes including hypernatremia with dehydration, disseminated intravascular coagulation, treatment with the chemotherapy agent L -asparaginase, and polycythemia. 11 Hypercoagulable states are also associated with SVT, with the most common including: protein C deficiency, protein S deficiency, antithrombin III deficiency, antiphospholipid antibody, and factor V Leiden. 12 Approximately 50% of SVT in childhood occurs in neonates and young infants. Mechanical distortion of the cerebral sinuses during the birth process may contribute to the propensity for SVT in newborns. However, cerebrovascular accidents such as SVT and acute ischemic stroke (AIS) are still very rare in childhood with an estimated incidence of 0.063 to 0.12 per 10,000 children with a ratio of AIS:SVT of 3:1.
12
Most children with SVT have an identifiable cause, with dehydration most common in neonates. The majority of children have more than a single identified risk factor.
Most of the literature concerning infant SVT consist of case reports or case series. 13 -16 It is known to be a fairly rare event for neonates. 11 However, approximately two thirds of infants with SVT presents with seizure activity. 11, 13 Seizures from SVT are not consistently focal, unlike unilateral cerebral infarction. 11 Slightly more than 50% of infants with central venous thrombosis present with lethargy, 11, 17 as did our patient. The unusual presentation of SVT in a term infant, with no readily identifiable cause in this case, prompted investigation for inherited prothrombotic risk factors. An association of SVT with thermolabile MTHFR has not previously been described in pediatric literature. 9,18 -22 Review of adult literature reveals that 12% to 21% of the general population is homozygous for the thermolabile MTHFR, 1,23 -25 and 35% of the population carries a heterozygous genotype. 26 -28 Thermolabile MTHFR has been shown to result in hyperhomocystinemia, which causes oxidative injury. Some studies have shown a chronic elevation of homocysteine to be a risk for thrombosis in adults. 25,28 -30 Other studies have failed to demonstrate increased risk of thrombosis. 31 -34 The situation in this report is intriguing since both mother and infant were both homozygous for thermolabile MTHFR. Obstetrical literature has noted that certain pregnant women who manifest infants with neural tube defects, 35, 36 abruptio placentae or infarction, 36,37 spontaneous abortions, 38 or preeclampsia 17 may demonstrate elevated plasma homocysteine levels. Also women who have pregnancy-related venous thromboembolism have an increased incidence of factor V Leiden and MTHFR mutation. 39 The metabolic consequence of thermolabile MTHFR is exacerbated by folic acid deficiency and can be abrogated by folic acid supplementation. 40 Malinow et al. 41 demonstrated a descending concentration gradient of homocysteine from maternal vein to umbilical veins and arteries, suggesting a transfer of homocysteine. We speculate that this mother had elevated levels of homocysteine during the pregnancy, which exposed the case patient to elevated homocysteine and increased his risk for SVT. Although this infant had no physical malformations, exposure to elevated homocysteine levels, even transiently in utero, may have led to endothelial abnormalities within the cerebral sinuses, which is one of the leading mechanisms by which hyperhomocysteinemia leads to thrombosis. 1 However, since we have no longitudinal data on plasma homocysteine levels for this mother prior to delivery, we present the homozygosity for thermolabile MTHFR for the mother and infant as an association and not as proven cause for the SVT complication.
Anticoagulation has not been demonstrated to improve outcome or alter the clinical course of infants or children with SVT. 12 We did not initiate anticoagulation in this infant primarily due to the associated areas of infarction and risk for secondary hemorrhage. The favorable outcome in this infant is encouraging; however, extended follow-up is necessary due to the propensity for late presentation of neurologic signs because of maturational central nervous system changes over the first year of life.
Symptomatic thrombotic events have been reported to occur in 0.07/10,000 children, 5.3/10,000 hospital admissions of children, and 2.4/1000 admissions of newborns to intensive care units. 42 Studies in developmental hemostasis have demonstrated that although newborns have approximately 50% of adult values of the vitamin K-dependent coagulation factors (II, VII, IX, X) and contact factors (XI, XII, prekallikrein, and high-molecular weight kininogen), the vitamin K-dependent anticoagulants (proteins C and S) are also low. 7 In turn, newborns have lower concentrations of antithrombin III and heparin cofactor II and demonstrate reduced fibrinolytic capacity. This places neonates at a greater risk of thromboembolic complications than older children. Data registries have demonstrated that the incidence of vascular accidents and other thromboembolic complications decreases significantly after the first year of life. 42 Although acquired risk factors for thromboembolic complications such as the use of central lines, sepsis, asphyxia, and dehydration predominate in the neonatal intensive care setting, thromboembolism is a multicausal pathology with contributions from both acquired and genetic risk factors. Even in the newborn setting, idiopathic thromboembolic complications should still invoke a search for underlying genetic prothrombotic risk factors. Continued clinical investigations across all pediatric age groups will eventually guide appropriate screening investigations for inherited thrombophilia, highlighting those genetic risk factors that are of most importance to neonates compared to older children and adults with thromboembolism.
This case report highlights several clinical points. SVT should be considered as an etiology for neonates with unexplained seizure activity, even if other factors such as hypernatremic dehydration are present. Inherited prothrombotic risk factors should be investigated and DNA analysis for MTHFR mutations should be considered for both the infant and mother.
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